First-Ever Drug Reverses Fatty Liver Damage!

A close-up view of a variety of colorful pills and tablets stacked together

A new experimental drug has shown remarkable results reversing liver damage in one of America’s fastest-growing and most deadly diseases — and it works in a way no approved treatment has attempted before.

Story Highlights

ION224, developed by Ionis Pharmaceuticals, targets a specific enzyme to reduce fat buildup in the liver, offering a first-of-its-kind approach to treating metabolic dysfunction-associated steatohepatitis (MASH).
In a Phase 2 clinical trial, 59% of patients on the highest dose met the primary endpoint compared to just 19% on placebo — a dramatic difference.
The drug is administered as a once-monthly injection and showed no treatment-related serious side effects or deaths during the trial.
Researchers call the results the first clinical evidence that blocking the DGAT2 enzyme can safely and effectively treat MASH, though larger Phase 3 trials are still needed before approval.

A Silent Epidemic Affecting Millions of Americans

Metabolic dysfunction-associated steatohepatitis, commonly known as MASH and previously called nonalcoholic steatohepatitis (NASH), is a severe form of fatty liver disease in which excess fat triggers dangerous inflammation and scarring of the liver. Left untreated, it can progress to cirrhosis, liver failure, or cancer. The condition is closely tied to obesity, type 2 diabetes, and metabolic syndrome — conditions that affect tens of millions of Americans and have been worsened by years of poor public health guidance and food policy failures.

Until recently, treatment options for MASH were extremely limited. Patients were largely told to lose weight and change their diet, with no targeted drug therapy available. The disease has quietly become one of the leading reasons Americans need liver transplants, making the search for an effective drug treatment urgent and long overdue.

How ION224 Targets the Root Cause

Researchers at the University of California San Diego led a Phase 2b clinical trial of ION224, a drug that works by blocking an enzyme called diacylglycerol acyltransferase 2, or DGAT2, which plays a central role in fat production in the liver. By targeting this enzyme directly, ION224 reduces the buildup of harmful fats that drive inflammation and tissue damage. The drug is delivered as a once-monthly subcutaneous injection, making it relatively convenient compared to daily oral medications.

The trial enrolled 160 participants who were randomly assigned to receive either a placebo or one of three doses of ION224 — 60 mg, 90 mg, or 120 mg — administered monthly. At the highest dose of 120 mg, 59% of patients met the primary endpoint, which measured meaningful improvement in liver tissue without worsening of fibrosis, compared to just 19% of those on placebo. ^[2] The 90 mg group also showed strong results, with 46% meeting the primary endpoint. ^[2]

Strong Results, But the Road to Approval Continues

Secondary endpoint data reinforced the headline finding. ION224 also outperformed placebo in achieving MASH resolution without fibrosis worsening, a critical marker of real disease improvement. ^[3] Researchers described these results as the first clinical evidence that blocking DGAT2 with an antisense drug — one that works at the genetic level to suppress enzyme production — can be both safe and effective in treating MASH. ^[1] No treatment-related serious adverse events or deaths occurred during the study. ^[7]

That said, the scientific community appropriately cautions that Phase 2b results, while highly encouraging, are not the final word. The MASH drug development landscape has seen promising early-stage results fail to hold up in larger confirmatory trials before. ^[2] Phase 3 trials involving more patients over longer timeframes will be necessary before the Food and Drug Administration (FDA) could consider approval. Still, the magnitude of improvement seen here — nearly triple the placebo response rate at the highest dose — gives researchers and patients genuine reason for optimism. For the millions of Americans quietly battling this disease, ION224 represents a meaningful step toward a real treatment option that targets the biological root of the problem rather than simply managing symptoms.